Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BMS-986435 in Healthy Chinese Participants
NCT06476821Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986435 in hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Time of maximum observed concentration and 1 more. Started Jun 2024; status: completed.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06476821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06476821.